Overview of HER2-Targeted Therapies in NSCLC

EP: 1.Value of Comprehensive Molecular Testing in NSCLC

EP: 2.Unmet Needs in HER2-Mutant NSCLC

EP: 3.Treatment of HER2-Mutant NSCLC: Consequences of Delays and Strategies to Improve Timely Initiation

Now Viewing

EP: 4.Overview of HER2-Targeted Therapies in NSCLC

In this episode, the panel provides an in-depth overview of current HER2-targeted therapies for non-small cell lung cancer (NSCLC), focusing on antibody-drug conjugates such as trastuzumab deruxtecan and tyrosine kinase inhibitors like zongertinib and sevabertinib. All therapies are currently recommended as second-line options after disease progression on standard systemic treatments. The discussion highlights how the choice among these agents depends on multiple factors, including the patient’s clinical status, toxicity profiles of each drug, and supporting efficacy data. Panelists emphasize the importance of shared decision-making, taking into account whether therapies are administered orally or intravenously, the specific trade-offs in side effect profiles, and individual patient goals or preferences. They also explore how conventional chemotherapy, immunotherapy, and targeted therapies differ in their mechanisms and impacts. Overall, the episode underlines the complexity of treatment selection and the need to tailor approaches based on both clinical evidence and patient-centered considerations.